Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

Company Performance - Viking Therapeutics, Inc. closed at $25.09, reflecting a -5.78% change from the previous day, which is less than the S&P 500's daily loss of 0.5% [1] - Over the past month, shares of Viking Therapeutics gained 0.04%, outperforming the Medical sector's loss of 0.7% but lagging behind the S&P 500's gain of 2.74% [1] Financial Expectations - Analysts expect Viking Therapeutics to report earnings of -$0.71 per share, indicating a year-over-year decline of 222.73% [2] - For the full year, the Zacks Consensus Estimates project earnings of -$2.48 per share and revenue of $0 million, reflecting changes of -145.54% and 0% respectively from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be noted, as positive revisions are interpreted as a good sign for business outlook [3] - The Zacks Rank system, which integrates estimate changes, currently ranks Viking Therapeutics at 4 (Sell), with the consensus EPS estimate moving 2.44% lower over the past month [5] Industry Context - Viking Therapeutics operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]